Key result
Device therapies for heart failure, including fluid monitoring, cardiac contractility modulation, and CIEDs, demonstrated symptomatic and prognostic benefits across multiple recent studies.
Answers are grounded in this paper and cite their sources.
This editorial provides a comprehensive overview of recent advancements and clinical outcomes associated with device therapies in heart failure management.
Inotropic agents did not improve outcomes in patients with heart failure (HF).1 Ahmad et al.2 summarize the results with inotropic agents in acute and chronic HF and discuss the main causes of failure and, importantly, give directions for future clinical studies. Safe and effective treatment of congestion remains a major unmet need.3, 4 Biegus et al.5 investigated the efficacy of adding to a standard diuretic-based regimen a device which continuously monitors urine output and delivers a matched volume of hydration fluid sufficient to maintain the set fluid balance rate. Patients with acute HF underwent 24 h of standard diuretic therapy followed by 24 h of diuretics with this device. The primary efficacy endpoint of actual fluid loss not exceeding the target fluid loss at the end of therapy was met in all patients. Diuresis was larger, patients' symptoms improved, central venous pressure decreased, and serum creatinine dropped with the new device.5 Body mass index (BMI) and the waist-to-hip ratio are major risk factors and prognostic variables in patients with HF.6, 7 Echouffo-Tcheugui et al.8 evaluated the association of BMI with HF outcomes in almost 19 000 patients with reduced left ventricular ejection fraction (LVEF) undergoing cardiac resynchronization therapy with defibrillation. They confirm an association between BMI and mortality similar to that described for the HF population in general. Compared to patients with a normal BMI, those underweight had a significantly higher risk of death and all-cause readmission at 3-year follow-up, whereas those overweight or with obesity had a lower mortality. Outcomes among BMI groups were not different in terms of device-related complications.8 Cardiac contractility modulation (CCM) improved symptoms and exercise tolerance and reduced HF hospitalizations in patients with chronic HF and a LVEF between 25% and 45%.9 Anker et al.10 reported the long-term results of a prospective multi-centre registry including 140 patients with chronic HF receiving CCM. In patients with LVEF ranging between 25% and 34% as well as in those with LVEF between 35% and 45%, CCM use was associated with symptom and quality of life improvement and reduced cardiovascular and HF hospitalizations. Three-year mortality was comparable to that predicted by the Seattle Heart Failure Model in the overall population and among patients with LVEF between 25% and 34%. Interestingly, it was lower than predicted in patients with LVEF between 35% and 45%.10 Right ventricular dysfunction and tricuspid regurgitation (TR) are major independent determinants of outcomes in patients with HF and valve disease.11 Transcatheter tricuspid valve repair (TTVR) by MitraClip is an emerging tool to treat patients with significant TR at high surgical risk.12 However, it is still unclear which patients would have a prognostic benefit. Schlotter et al.13 reported procedural and clinical outcomes of 164 patients undergoing TTVR for TR stratified into four aetiology-based clinical scenarios (CSs): Dialysis-CS, mitral regurgitation ≥3 CS, pulmonary artery systolic pressure ≥50 mmHg (PAPs-CS), and atrial fibrillation CS. Procedural success was high and did not vary across CSs. Among patients with procedural success, PAPs-CS had the highest rate of the primary endpoint (death, HF hospitalization or reintervention) while mortality rates were comparable in PAPs-CS and Dialysis-CS, and higher compared to the other two CSs. Improvements in functional status were observed in the majority of patients regardless of their CS.13 Left ventricular assist device (LVAD) is an established treatment of advanced HF.1, 14 It is not clear whether a cardiac implantable electronic device (CIED) is still useful in LVAD carriers. Cikes et al.15 compared the clinical characteristics and outcomes of 448 LVAD carriers with or without a CIED with an active defibrillator component. At the time of LVAD implantation, 235 patients (52%) had an active CIED. The adjusted relative risk of all-cause death was reduced by ≈40% in patients with an active CIED compared to those who did not. Elderly age, LVAD implantation as a redo procedure, number of clinically significant ventricular arrhythmia episodes pre-LVAD, and use of vasopressors were also significant predictors of all-cause mortality.15 Exercise training has a major role in HF treatment.16 Piepoli et al.17 reported regional differences in the Exercise Training in HF survey. Greater implementation of exercise training procedures was observed in Western and Northern European areas, whereas lower rates were noted in Southern, Eastern European and extra-European regions. The main reasons of poor implementation are the lack of resources and the exclusion of exercise training programmes from national and local guidelines.
No takes yet. Share an insight, caveat, or question.
Adamo et al. (2019) conducted a review in Heart failure. Device therapies was evaluated. Device therapies for heart failure, including fluid monitoring, cardiac contractility modulation, and CIEDs, demonstrated symptomatic and prognostic benefits across multiple recent studies.
Synapse has enriched 10 related papers. Consider them for comparative context: